Laboratory of Biophysics and Medical Technologies of Tunis, 9 Zouhair Essafi Street, 1006, Tunis, Tunisia.
University of Tunis Elmanar, Farhat Hached University Campus Tunis, B.P. No. 94-ROMMANA, 1068, Tunis, Tunisia.
Radiat Environ Biophys. 2021 May;60(2):289-298. doi: 10.1007/s00411-021-00907-9. Epub 2021 Apr 2.
When planning treatment for Graves' disease with I, the effective half-life (T) should be estimated individually as it depends on biological characteristics such as iodine uptake and excretion, which differ from an individual to another (Berg et al. 1996). All the methods to quantify T described in the literature are quite complex and are difficult to be used in clinical routine. With the aim of optimizing this process, a simplified method is proposed here to evaluate T of I during treatment of Graves' disease. The present study suggests improving the method of determining T based on thermoluminescence dosimetry. This involves implementing a new method and includes reduction of TLD (Thermoluminescent Dosimeter) measurements. The proposed method was validated on patients with Graves' disease. The radiation dose delivered to the patients was determined using the MIRD (Medical Internal Radiation Dosimetry) formalism. The relative difference between T obtained based on seven measurement intervals at [0-24 h, 24-48 h, 48-72 h, 72-96 h, 96-120 h, 120-144 h, 144-168 h] and based on three measurement intervals at [0-24 h, 72-96 h, 144-168 h] and [0-24 h, 120-144 h, 144-168 h] was 1.9% and 3.81%, respectively. Comparison of doses obtained based on a general T and on a personalized T gave a statistically significant difference with a correlation coefficient Rof 0.44. The T obtained from just three measurements was found to be sufficiently accurate and easily applicable. The results obtained demonstrate the need to determine and use personalized T values instead of using a fixed value of 7 days.
在使用 I 治疗 Graves 病时，应根据碘摄取和排泄等生物学特性单独估计有效半衰期 (T)，因为这些特性因人而异 (Berg 等人，1996 年)。文献中描述的所有量化 T 的方法都非常复杂，难以在临床常规中使用。为了优化这个过程，这里提出了一种简化的方法来评估 Graves 病治疗期间 I 的 T。本研究建议改进基于热释光剂量测定法的 T 测定方法。这涉及实施一种新方法，包括减少 TLD（热释光剂量计）测量。该方法在 Graves 病患者中进行了验证。采用 MIRD（医学内部辐射剂量学）公式确定患者接受的辐射剂量。基于七个测量间隔[0-24 h、24-48 h、48-72 h、72-96 h、96-120 h、120-144 h、144-168 h]和基于三个测量间隔[0-24 h、72-96 h、144-168 h]和[0-24 h、120-144 h、144-168 h]获得的 T 与基于三个测量间隔[0-24 h、120-144 h、144-168 h]获得的 T 之间的相对差异分别为 1.9%和 3.81%。基于通用 T 和个性化 T 获得的剂量之间的比较具有统计学显著性差异，相关系数 R 为 0.44。仅通过三次测量获得的 T 被发现足够准确且易于应用。结果表明，需要确定和使用个性化 T 值，而不是使用 7 天的固定值。
